Concepedia

Danielle Porter

DP

Statistics

Publications

58

Citations

8.4K

H-Index

36

Active since

2012

Affiliations

Gilead Sciences (United States)(Current)

University of North Carolina at Chapel Hill

University of Alberta

The University of Texas Medical Branch at Galveston

Universität Hamburg

Danielle Porter is an author at Gilead Sciences (United States) specializing in antiviral therapy, infectious diseases, and antiviral pharmacotherapy.

ORCID

Publications per year

2012–2024

58

Publications

58

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan, Amy Sims, Sarah R. Leist et al. · Nature Communications · 2020 · 1.8K citations · Full text

, , +12

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Calvin J. Gordon, Egor P. Tchesnokov, Emma Woolner et al. · Journal of Biological Chemistry · 2020 · 1K citations · Full text

, , +16

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Calvin J. Gordon, Egor P. Tchesnokov, Joy Y. Feng et al. · Journal of Biological Chemistry · 2020 · 890 citations · Full text

, , +17

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Brandi N. Williamson, Friederike Feldmann, Benjamin Schwarz et al. · Nature · 2020 · 740 citations · Full text

, , +14

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Egor P. Tchesnokov, Joy Y. Feng, Danielle Porter et al. · Viruses · 2019 · 657 citations · Full text

, , +17

1–5 of 58